Onco Wiki / Bandera roja

Infección crónica por helicobacter pylori (prueba positiva de respiración de urea, antígeno heces, gástrico...

Vista determinista de la entidad fuente YAML. La autoridad clínica sigue con los ID de fuente citados y estado de firma del revisor.

IDRF-CHRONIC-H-PYLORI-MALIGNANCY-PREVENTION
TipoSeñal de alerta
Situaciónreviewed 2026-05-18 | pending_clinical_signoff
EnfermedadesDIS-GASTRIC
FuentesSRC-NCCN-BCELL-2025

Origen de la bandera roja

DefiniciónChronic Helicobacter pylori infection (positive urea breath test, stool antigen, gastric biopsy histology, or stool PCR) in an individual without a current gastric malignancy diagnosis. IARC Group 1 carcinogen (H. pylori) — established etiological driver of gastric adenocarcinoma (intestinal-type primarily) and gastric MALT lymphoma. Eradication therapy reduces gastric-cancer incidence (NNT ~15 in high-incidence populations per Cochrane meta-analyses) and is curative for early-stage gastric MALT lymphoma in ~70-80% of cases (Wotherspoon regression). Prevention-persona RedFlag (§20 ratification 2026-05-18).
Dirección clínicainvestigación
Categoríaotros

Lógica de activación

{
  "any_of": [
    {
      "finding": "h_pylori_status",
      "value": "positive"
    },
    {
      "finding": "urea_breath_test",
      "value": "positive"
    },
    {
      "finding": "h_pylori_stool_antigen",
      "value": "positive"
    },
    {
      "finding": "h_pylori_biopsy_histology",
      "value": "positive"
    }
  ],
  "type": "lab_value"
}

Notas

Prevention-persona RedFlag (CHARTER §3 amended 2026-05-18 Path A, HCP-mediated). Fires when patient profile shows chronic H. pylori (positive UBT / stool antigen / biopsy histology / stool PCR) AND no confirmed gastric malignancy. Engine routes such patients to a PreventionPlan recommending eradication therapy (per IND-H-PYLORI-PREVENTION-ERADICATION) as the etiological-cancer- prevention pathway. Evidence for H. pylori → gastric cancer causation (IARC Group 1): multiple Cochrane meta-analyses show eradication reduces gastric adenocarcinoma incidence (RR ~0.54-0.66, NNT ~15-50 depending on population baseline incidence). Effect is stronger in high-incidence populations and in younger individuals where atrophic gastritis / intestinal metaplasia has not yet developed. Evidence for H. pylori → gastric MALT lymphoma: eradication is the first-line treatment for early-stage gastric MALT lymphoma, with Wotherspoon regression in ~70-80% of cases (especially t(11;18)- negative). This is treatment-persona territory (existing MALT lymphoma in setting of confirmed H. pylori → treatment Indication, not yet authored) — distinct from prevention persona (chronic H. pylori → prevent MALT/adenocarc...

Utilizado por

Indicación